Get the Stockscreener App
120.94
0.17%
0.20
Overview
News
Price History
Option Chain
Financials
Why GILD Down?
Discussions
Forecast
Stock Split
Dividend History
Gilead Sciences Inc stock is traded at $120.94, with a volume of 5.40M.
It is up +0.17% in the last 24 hours and up +6.40% over the past month.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$120.74
Open:
$120.415
24h Volume:
5.40M
Relative Volume:
0.80
Market Cap:
$150.06B
Revenue:
$28.80B
Net Income/Loss:
$6.31B
P/E Ratio:
24.06
EPS:
5.0273
Net Cash Flow:
$9.37B
1W Performance:
-1.52%
1M Performance:
+6.40%
6M Performance:
+13.93%
1Y Performance:
+36.22%
1-Day Range:
$118.70
$121.14
1-Week Range:
$118.70
$124.61
52-Week Range:
$86.08
$124.61
Gilead Sciences Inc Stock (GILD) Company Profile
Name
Gilead Sciences Inc
Sector
Industry
Phone
(650) 574-3000
Address
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
120.94 | 149.82B | 28.80B | 6.31B | 9.37B | 5.0273 |
|
LLY
Lilly Eli Co
|
825.45 | 736.03B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
190.40 | 463.72B | 92.15B | 25.12B | 18.18B | 10.36 |
|
ABBV
Abbvie Inc
|
227.99 | 403.22B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
130.36 | 254.84B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
87.49 | 217.76B | 63.43B | 16.42B | 14.72B | 6.4861 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Aug-08-25 | Upgrade | Truist | Hold → Buy |
| Jul-25-25 | Upgrade | Needham | Hold → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-04-25 | Reiterated | Oppenheimer | Outperform |
| Feb-18-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-13-25 | Upgrade | DZ Bank | Hold → Buy |
| Jan-10-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Nov-08-24 | Downgrade | Maxim Group | Buy → Hold |
| Oct-21-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-08-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-24 | Reiterated | Maxim Group | Buy |
| Apr-24-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Feb-22-24 | Downgrade | Truist | Buy → Hold |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Sep-08-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Reduce |
| Jul-24-23 | Reiterated | Barclays | Equal Weight |
| May-16-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-28-23 | Resumed | Piper Sandler | Overweight |
| Jan-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-13-22 | Resumed | BofA Securities | Neutral |
| Dec-09-22 | Downgrade | DZ Bank | Buy → Hold |
| Oct-31-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-28-22 | Reiterated | BMO Capital Markets | Market Perform |
| Oct-28-22 | Reiterated | Cowen | Outperform |
| Oct-28-22 | Reiterated | JP Morgan | Overweight |
| Oct-28-22 | Reiterated | Jefferies | Buy |
| Oct-28-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-28-22 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-28-22 | Upgrade | Truist | Hold → Buy |
| Oct-28-22 | Reiterated | Wells Fargo | Equal Weight |
| Oct-04-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-28-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-02-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-02-22 | Reiterated | BofA Securities | Neutral |
| Feb-02-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-02-22 | Reiterated | Truist | Hold |
| Feb-02-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Argus | Hold → Buy |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-19-21 | Resumed | Piper Sandler | Neutral |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Jul-30-21 | Reiterated | BMO Capital Markets | Market Perform |
| Jul-30-21 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-01-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-30-21 | Upgrade | Redburn | Neutral → Buy |
| Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-03-20 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Sep-30-20 | Resumed | Jefferies | Buy |
| Sep-15-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-31-20 | Reiterated | Credit Suisse | Neutral |
| Jul-31-20 | Reiterated | Morgan Stanley | Equal-Weight |
| Jul-31-20 | Reiterated | Piper Sandler | Overweight |
| Jul-31-20 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-31-20 | Reiterated | SunTrust | Hold |
| Jul-31-20 | Reiterated | Wells Fargo | Equal Weight |
| Jul-20-20 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jun-03-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-26-20 | Upgrade | SunTrust | Sell → Hold |
| May-01-20 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-20 | Downgrade | SunTrust | Hold → Sell |
| Apr-27-20 | Downgrade | UBS | Buy → Neutral |
| Apr-20-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Apr-20-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Downgrade | CFRA | Hold → Sell |
View All
Gilead Sciences Inc Stock (GILD) Latest News
Will Gilead Sciences Inc. stock remain a Wall Street favorite2025 Support & Resistance & Free Technical Pattern Based Buy Signals - newser.com
What To Expect From Gilead In Q3 2025 (NASDAQ:GILD) - Seeking Alpha
Gilead Sciences patents new PI3Kα inhibitors - BioWorld MedTech
Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta - BioSpace
Precision Trading with Gilead Sciences Inc. (GILD) Risk Zones - news.stocktradersdaily.com
TD Cowen Raises Price Target for Gilead Sciences (GILD) to $125 | GILD Stock News - GuruFocus
Commentary: A breakthrough to prevent HIV shouldn’t break the bank - The Boston Globe
Gilead Sciences Rallies 32% in 2025 Are Shares Trading Below Their True Value - Yahoo Finance
Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Wolfe Research Adjusts Gilead Sciences Price Target to $140 From $135, Maintains Outperform Rating - MarketScreener
TD Cowen Adjusts Gilead Sciences Price Target to $125 From $115, Maintains Buy Rating - MarketScreener
Gilead to present new data on Livdelzi for PBC at Liver Meeting 2025 - Investing.com
Gilead to present liver disease data at AASLD conference - StreetInsider
(Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta - Business Wire
Using economic indicators to assess Gilead Sciences Inc. potentialJuly 2025 Trade Ideas & Smart Money Movement Alerts - newser.com
Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
CVS (CVS) Delays Adding Gilead's Yeztugo Over Pricing Concerns - GuruFocus
Gilead Sciences (GILD) Halts Phase 1 HIV Treatment Trial - GuruFocus
Gilead discontinues early-stage trial for long-acting injectable for HIV - Seeking Alpha
Gilead Sciences stock rating reiterated by RBC amid HIV drug setback - Investing.com
Gilead Sciences (GILD) Halts Phase 1 Study for HIV Treatment - GuruFocus
CVS Caremark tells AIDS activists Gilead needs to lower the price of its new HIV drug to get on formularies - statnews.com
What to Expect From Gilead Sciences' Next Quarterly Earnings Report - Barchart.com
Exit strategy if you’re trapped in Gilead Sciences Inc.Quarterly Investment Review & Low Risk Investment Opportunities - newser.com
Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia - GlobeNewswire Inc.
How to build a dashboard for Gilead Sciences Inc. stockJuly 2025 Pullbacks & Verified Momentum Stock Watchlist - newser.com
Health Canada conditionally approves Gilead Sciences’ Lyvdelzi for PBC - Pharmaceutical Technology
Is Gilead Sciences Inc. (Common Stock) (GIS0) stock a momentum leaderEarnings Recap Report & Entry Point Confirmation Alerts - newser.com
Will Gilead Sciences Inc. (Common Stock) (GIS0) stock enhance shareholder value2025 Risk Factors & Reliable Breakout Forecasts - newser.com
Will Gilead Sciences Inc. outperform the marketDividend Hike & Daily Volume Surge Trade Alerts - newser.com
Why Gilead Sciences Inc. (Common Stock) (GIS0) stock attracts wealthy investorsEarnings Beat & Free Weekly Watchlist of Top Performers - newser.com
Will Gilead Sciences Inc. (Common Stock) (GIS0) stock boost dividends furtherMarket Trend Report & Capital Protection Trade Alerts - newser.com
Is Gilead Sciences Inc. stock cheap at current valuationJuly 2025 Price Swings & High Accuracy Trade Signal Alerts - newser.com
Gilead agrees not to raise prices on HIV medicines for state AIDS drug programs - statnews.com
100 Organizations Denounce Gilead on Price Hikes Gutting ADAP - AIDS Healthcare Foundation
LYVDELZI® (SELADELPAR) RECEIVES HEALTH CANADA APPROVAL FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS - BioSpace
LYVDELZI® RECEIVES HEALTH CANADA APPROVAL FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS - Investing News Network
AHF: 80 Organizations Denounce Gilead on Price Hikes Gutting ADAP - Yahoo Finance
What makes Gilead Sciences Inc. (Common Stock) (GIS0) stock appealing to growth investorsWeekly Loss Report & Weekly Watchlist of Top Performers - newser.com
Is Gilead Sciences Inc. (GIS) stock inflation resilientWeekly Trading Summary & Weekly Stock Breakout Alerts - newser.com
Targets Report: Will Gilead Sciences Inc. (GIS) stock extend growth storyJuly 2025 Chart Watch & Safe Entry Point Alerts - nchmf.gov.vn
Is Gilead Sciences Inc. stock bottoming outTrade Analysis Summary & AI Enhanced Market Trend Forecasts - newser.com
Gilead Sciences (GILD): Assessing Valuation After Major Trodelvy Breast Cancer Breakthrough and HIV Advances - simplywall.st
Gilead to spotlight new virology data across HIV, viral hepatitis and respiratory diseases at IDWeek 2025 - European AIDS Treatment Group
How Gilead Sciences Inc. (Common Stock) (GIS0) stock trades after rate cutsEarnings Trend Report & Real-Time Buy Signal Alerts - newser.com
Will Gilead Sciences Inc. stock keep outperforming rivalsMarket Growth Summary & Breakout Confirmation Alerts - newser.com
Can Gilead Sciences Inc. hit a new high this monthQuarterly Trade Review & Short-Term High Return Strategies - newser.com
Will Gilead Sciences Inc. (Common Stock) (GIS0) stock announce a stock splitAnalyst Downgrade & Smart Allocation Stock Tips - newser.com
Will Gilead Sciences Inc. (GIS) stock deliver compounding returnsQuarterly Risk Review & Verified Swing Trading Watchlists - nchmf.gov.vn
Fed Watch: Is Gilead Sciences Inc. (GIS) stock inflation resilientJuly 2025 Earnings & Low Volatility Stock Recommendations - nchmf.gov.vn
Aug Shorts: Will Gilead Sciences Inc. (Common Stock) (GIS0) stock announce a stock splitJuly 2025 Catalysts & Expert Curated Trade Setup Alerts - nchmf.gov.vn
Gilead Sciences Inc Stock (GILD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Gilead Sciences Inc Stock (GILD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mercier Johanna | Chief Commercial Officer |
Oct 15 '25 |
Sale |
118.08 |
3,000 |
354,240 |
110,193 |
0.39%
0.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):